Arrowhead Pharmaceuticals... (ARWR)
| Bid | 14.82 |
| Market Cap | 2.2B |
| Revenue (ttm) | 545.21M |
| Net Income (ttm) | -146.55M |
| EPS (ttm) | -1.24 |
| PE Ratio (ttm) | -12.87 |
| Forward PE | -4.56 |
| Analyst | Buy |
| Ask | 16.99 |
| Volume | 755,797 |
| Avg. Volume (20D) | 1,852,062 |
| Open | 15.84 |
| Previous Close | 15.51 |
| Day's Range | 15.44 - 16.07 |
| 52-Week Range | 9.57 - 30.41 |
| Beta | 0.95 |
About ARWR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in June 2025 Investor ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Glo...
1 month ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Chris...
1 month ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in May 2025 Investor ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securiti...
1 month ago · businesswire.com
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss ...
2 months ago · businesswire.com
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial OfficerPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will reti...
